Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 4;30(11):2027-2036.
doi: 10.1093/ibd/izad280.

Factors Associated With Extraintestinal Manifestations of Inflammatory Bowel Disease in SPARC-IBD

Madeline Alizadeh  1   2 , Kiran Motwani  2 , Bernadette C Siaton  3 , Ameer Abutaleb  4 , Jacques Ravel  1 , Raymond K Cross  2 ; SPARC-IBD Investigators
Collaborators, Affiliations

Factors Associated With Extraintestinal Manifestations of Inflammatory Bowel Disease in SPARC-IBD

Madeline Alizadeh et al. Inflamm Bowel Dis. .

Erratum in

Abstract

Background: Extraintestinal manifestations (EIMs) of inflammatory bowel diseases (IBDs) are a common and debilitating feature of disease, occurring in up to 40% of patients with IBD, yet predicting who may develop them is difficult. The goal of our study was to better characterize which patients may be at highest risk of developing not only 1 EIM, but also multiple EIMs, across both diseases.

Methods: A retrospective study of participants enrolled in the SPARC IBD (Study of Prospective Adult Research Cohort with IBD) registry was performed, and demographic and clinical data were analyzed. A total of 1211 patients with data available on EIMs were included, and differences among variables with vs without EIMs were assessed.

Results: A total of 329 participants with at least 1 EIM were identified, compared with 882 participants without any EIMs. Crohn's disease patients and women were more likely to have 2 or more EIMs (P = .005 and P ≤ .001, respectively). Participants with ocular manifestations were likeliest to have at least 2 EIMs (P ≤ .001). Even when diagnosis was controlled for, involvement of the right colon (P = .021) was predictive of IBD-associated arthritis across both diseases in a multivariate generalized linear model.

Conclusions: This is the first comprehensive large-cohort assessment of how EIMs relate to one another at the individual vs systems levels. Further, our analysis is the first to recognize specific locations of colon involvement associated with EIMs of IBD, regardless of IBD type. These results are important in identifying patients at risk of developing future EIMs and may help with risk stratification when choosing treatments.

Keywords: SPARC; extraintestinal manifestations; inflammatory bowel disease.

Plain language summary

Although extraintestinal manifestations frequently complicate inflammatory bowel disease, predicting those at highest risk of developing them is difficult. We found female patients with Crohn’s disease, ocular, and dermatologic manifestations are likeliest to develop multiple extraintestinal manifestations. Further, we found right-sided involvement is predictive of inflammatory bowel disease–associated arthritis.

PubMed Disclaimer

Conflict of interest statement

R.K.C. has received income from consulting and participation in advisory boards for AbbVie, BMS, Fzata, Fresenius Kabi, Janssen, Magellan Health, Samsung Bioepis, Sebela, and Takeda; served on the Data Safety Monitoring Board for Adiso; served as a member of the Executive Committee for the IBD Education Group; and served as a Scientific Co-Director for the CorEvitas Registry. All other authors have no conflicts of interest to report.

Figures

Figure 1.
Figure 1.
The distribution of those who experience 1, 2, or 3 extraintestinal manifestations (EIMs) for each individual EIM. PSC, primary sclerosing cholangitis.
See this image and copyright information in PMC

References

    1. Xu F, Liu Y, Wheaton AG, Rabarison KM, Croft JB.. Trends and factors associated with hospitalization costs for inflammatory bowel disease in the United States. Appl Health Econ Health Policy. 2019;17(1):77-91. doi: 10.1007/s40258-018-0432-4 - DOI - PMC - PubMed
    1. Vavricka SR, Schoepfer A, Scharl M, et al. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(8):1982-1992. doi: 10.1097/mib.0000000000000392d - DOI - PMC - PubMed
    1. Levine JS, Burakoff R.. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Hepatol. 2011;7(4):235-241. - PMC - PubMed
    1. Veloso FT. Extraintestinal manifestations of inflammatory bowel disease: do they influence treatment and outcome? World J Gastroenterol. 2011;17(22):2702-2707. doi: 10.3748/wjg.v17.i22.2702 - DOI - PMC - PubMed
    1. Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106(1):110-119. doi: 10.1038/ajg.2010.343 - DOI - PubMed

Publication types